CA2386088A1 - Peptides antigeniques mage-a12 et utilisation - Google Patents

Peptides antigeniques mage-a12 et utilisation Download PDF

Info

Publication number
CA2386088A1
CA2386088A1 CA002386088A CA2386088A CA2386088A1 CA 2386088 A1 CA2386088 A1 CA 2386088A1 CA 002386088 A CA002386088 A CA 002386088A CA 2386088 A CA2386088 A CA 2386088A CA 2386088 A1 CA2386088 A1 CA 2386088A1
Authority
CA
Canada
Prior art keywords
mage
hla
amino acid
peptides
binding peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386088A
Other languages
English (en)
Inventor
Leonora Heidecker
Benoit Van Den Eynde
Thierry Boon-Falleur
Francis Brasseur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386088A1 publication Critical patent/CA2386088A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des peptides antigéniques dérivés de polypeptides MAGE-A12 et présentés par des molécules HLA. L'invention concerne également des procédés de diagnostic et de traitement faisant intervenir ces polypeptides.
CA002386088A 1999-10-19 2000-10-19 Peptides antigeniques mage-a12 et utilisation Abandoned CA2386088A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16037499P 1999-10-19 1999-10-19
US60/160,374 1999-10-19
US17957000P 2000-02-01 2000-02-01
US60/179,570 2000-02-01
PCT/US2000/028852 WO2001029220A2 (fr) 1999-10-19 2000-10-19 Peptides antigeniques mage-a12 et utilisation

Publications (1)

Publication Number Publication Date
CA2386088A1 true CA2386088A1 (fr) 2001-04-26

Family

ID=26856840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386088A Abandoned CA2386088A1 (fr) 1999-10-19 2000-10-19 Peptides antigeniques mage-a12 et utilisation

Country Status (8)

Country Link
EP (1) EP1222274A2 (fr)
JP (1) JP2003512057A (fr)
KR (1) KR20020047249A (fr)
CN (1) CN1402782A (fr)
AU (1) AU1335601A (fr)
CA (1) CA2386088A1 (fr)
HK (1) HK1046925A1 (fr)
WO (1) WO2001029220A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
EP1188446B1 (fr) 2000-09-15 2009-08-05 Institut Pasteur Vecteurs de matériaux protéiniques pour le transport de molécules vers les cellules exprimant le CD11b
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
AU2002352355B2 (en) * 2001-12-05 2008-04-03 Sengenics Corporation Pte Ltd Protein arrays for allelic variants and uses thereof
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
DE602004024440D1 (de) 2003-11-21 2010-01-14 Pasteur Institut Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
AU2014227019B2 (en) * 2013-03-08 2016-10-27 Taiho Pharmaceutical Co., Ltd. Novel peptide having 5 linked CTL epitopes
EP3061771B1 (fr) 2013-10-21 2020-04-15 Taiho Pharmaceutical Co., Ltd. Nouveau peptide à quatre épitopes ctl

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5487974A (en) 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
WO1994016713A1 (fr) 1993-01-22 1994-08-04 Ludwig Institute For Cancer Research Procede d'identification et de traitement de sujets porteurs de cellules cancereuses qui expriment le clone 10 de hla-c/mage-1
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5610013A (en) 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5589334A (en) 1994-06-03 1996-12-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules

Also Published As

Publication number Publication date
JP2003512057A (ja) 2003-04-02
WO2001029220A3 (fr) 2002-03-07
WO2001029220A2 (fr) 2001-04-26
AU1335601A (en) 2001-04-30
EP1222274A2 (fr) 2002-07-17
HK1046925A1 (zh) 2003-01-30
CN1402782A (zh) 2003-03-12
KR20020047249A (ko) 2002-06-21

Similar Documents

Publication Publication Date Title
US7371845B2 (en) MAGE-A3 peptides presented by HLA class II molecules
EP1119623B1 (fr) Peptides du gene mage-a3 presentes par les molecules de hla classe ii
JP4652390B2 (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ１ペプチド
US7311914B2 (en) MAGE-A4 antigenic peptides and uses thereof
US9200047B2 (en) SSX-2 peptides presented by HLA class II molecules
CA2386088A1 (fr) Peptides antigeniques mage-a12 et utilisation
AU765669B2 (en) Tumour rejection antigens
US6716809B1 (en) Mage-A3 peptides presented by HLA class molecules
US6897288B1 (en) Mage-A12 antigenic peptides and uses thereof
EP1165776A1 (fr) PEPTIDES ANTIGENIQUES EphA3 DE RECEPTEUR DE TYROSINE KINASE
EP1109568A1 (fr) Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages
AU2002339748A1 (en) MAGE-A3 peptides presented by HLA class II molecules

Legal Events

Date Code Title Description
FZDE Discontinued